Global Head of Science

• May 2021 - Present

Director Business Development - Asia Pacific

• Sep 2018 - May 2021

After relocating to Australia, I switched roles and my current focus is growing the Phynova business in the Asia Pacific region, whilst providing technical and scientific support to the US and EU operations. In my role as Director of Business Development I am responsible for market entry (regulatory), customer development, technical sales, scientific due diligence, and working with the R&D team to design and run value-adding clinical trials to support commercialisation as well as new product development and product/application improvements. I work closely with our global distribution partner, DSM, in a wide range of functions including quality, regulatory, R&D, sales, and marketing. Show less

Chief Operating Officer

• May 2014 - Sep 2018

As a member of the leadership team, I had responsibility to drive product development (product optimisation, clinical development, regulatory approvals) and innovation to move the company from a pure R&D business to one that is revenue generating.

Programme Manager

• Jun 2009 - May 2014

Oversee the development of the company pipeline in RX, OTC, and cosmetic products.Budgeting and forecasting R&D development costs and revenuesProject valuations and new opportunities evaluationBusiness developmentInternal management of intellectual property portfolioTherapeutic expertise: Hepatitis C, resistant bacteria (MRSA), infectious diseases (esp flaviviruses such as HCV and dengue fever), postoperative ileus, metabolic disorders including non-alcoholic fatty liver disease/steatohepatitis, type-2 diabetes, obesity, hyperpigmentation disorders Show less

Director

• Sep 2018 - Present

Proposal Business Analyst

• Jan 2009 - May 2009

Development of clinical trial proposals for prospective pharmaceutical company clients Development of clinical trial proposals for prospective pharmaceutical company clients

Project Manager

• Apr 2007 - Dec 2008

Clinical project management of chronic hepatitis C Phase I/II study Project management of several preclinical candidates Therapeutic expertise: Hepatitis C, resistant bacteria (MRSA), infectious diseases (esp flaviviruses such as HCV and dengue fever), postoperative ileus, metabolic disorders including non-alcoholic fatty liver disease/steatohepatitis, type-2 diabetes, obesity Clinical project management of chronic hepatitis C Phase I/II study Project management of several preclinical candidates Therapeutic expertise: Hepatitis C, resistant bacteria (MRSA), infectious diseases (esp flaviviruses such as HCV and dengue fever), postoperative ileus, metabolic disorders including non-alcoholic fatty liver disease/steatohepatitis, type-2 diabetes, obesity